Is ibogaine legal in United States?
Ibogaine is a Schedule I controlled substance in the United States; treatment is not legally available anywhere in the country.
Under the federal Controlled Substances Act, ibogaine is Schedule I in all 50 states and the District of Columbia. No clinic in the United States can legally administer ibogaine treatment.
On April 18, 2026, a federal Executive Order directed a coordinated effort to prioritize ibogaine research, accelerate clinical development, and modernize regulatory pathways for emerging therapies, with a specific focus on Veterans. The order does not change ibogaine's Schedule I status or create a regulated treatment pathway inside the United States.
Several states have moved on ibogaine-related policy at the state level. Texas Governor Greg Abbott signed SB 2308 in June 2025, creating a $50M fund for FDA clinical trials; in April 2026 the Texas Health and Human Services Commission awarded that fund to UTHealth Houston and UTMB Galveston for the IMPACT consortium. California Governor Gavin Newsom signed AB 1103 in October 2025, streamlining state approval for federally authorized Schedule I research through December 2027. New York has multiple pending research bills (including S1817/A1522 and A9583) as of April 2026. Americans for Ibogaine tracks 18 U.S. states with active ibogaine-relevant legislation.
None of this state-level activity creates a legal treatment pathway for U.S. residents. Research funds and research-enabling bills support FDA clinical trials — not clinic access. The physician-prescribed option for Americans remains Brazil, where ibogaine is regulated by ANVISA and administered in licensed hospitals by independent Brazilian physicians.
Brazil is the world's leading country for physician-prescribed, hospital-administered ibogaine. Treatment is regulated by ANVISA (Brazil's federal health agency, the equivalent of the FDA), prescribed by licensed physicians, and delivered with full cardiac telemetry and hospital emergency infrastructure.
City guides
Local guides for major metros — each page covers travel, legal context, and what americans should know before booking a discovery call.
- AnaheimCalifornia · coming soon
- ArlingtonTexas · coming soon
- AspenColorado · coming soon
- AuroraColorado · coming soon
- AustinTexas · coming soon
- BoulderColorado · coming soon
- BuffaloNew York · coming soon
- Cape CoralFlorida · coming soon
- ChandlerArizona · coming soon
- ChesapeakeVirginia · coming soon
- CincinnatiOhio · coming soon
- ClevelandOhio · coming soon
- Colorado SpringsColorado · coming soon
- ColumbusOhio · coming soon
- Corpus ChristiTexas · coming soon
- DallasTexas
- DenverColorado · coming soon
- DetroitMichigan · coming soon
- EdisonNew Jersey · coming soon
- El PasoTexas · coming soon
- Fort WorthTexas · coming soon
- FriscoTexas · coming soon
- GarlandTexas · coming soon
- GilbertArizona · coming soon
- GlendaleArizona · coming soon
- HialeahFlorida · coming soon
- HoustonTexas
- IrvineCalifornia · coming soon
- IrvingTexas · coming soon
- JacksonvilleFlorida · coming soon
- Jersey CityNew Jersey · coming soon
- LaredoTexas · coming soon
- Las VegasNevada · coming soon
- LexingtonKentucky · coming soon
- Long BeachCalifornia · coming soon
- Los AngelesCalifornia
- LouisvilleKentucky · coming soon
- LubbockTexas · coming soon
- McKinneyTexas · coming soon
- MesaArizona · coming soon
- MiamiFlorida
- New York CityNew York
- NewarkNew Jersey · coming soon
- NorfolkVirginia · coming soon
- OaklandCalifornia · coming soon
- Oklahoma CityOklahoma · coming soon
- OrlandoFlorida · coming soon
- PhoenixArizona · coming soon
- PlanoTexas · coming soon
- Port St. LucieFlorida · coming soon
- PortlandOregon · coming soon
- PrincetonNew Jersey · coming soon
- RichmondVirginia · coming soon
- SacramentoCalifornia · coming soon
- Salt Lake CityUtah · coming soon
- San AntonioTexas · coming soon
- San DiegoCalifornia · coming soon
- San FranciscoCalifornia · coming soon
- San JoseCalifornia · coming soon
- ScottsdaleArizona · coming soon
- SeattleWashington · coming soon
- St. PetersburgFlorida · coming soon
- TampaFlorida · coming soon
- TrentonNew Jersey · coming soon
- TucsonArizona · coming soon
- TulsaOklahoma · coming soon
- Virginia BeachVirginia · coming soon
Browse by state
- Alabama
- Alaska
- Arizona7 cities
- Arkansas
- California9 cities
- Colorado5 cities
- Connecticut
- Delaware
- District of Columbia
- Florida8 cities
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky2 cities
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan1 city
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada1 city
- New Hampshire
- New Jersey5 cities
- New Mexico
- New York2 cities
- North Carolina
- North Dakota
- Ohio3 cities
- Oklahoma2 cities
- Oregon1 city
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas15 cities
- Utah1 city
- Vermont
- Virginia4 cities
- Washington1 city
- West Virginia
- Wisconsin
- Wyoming
Why Americans travel to Brazil
Americans who have exhausted conventional addiction or mental-health treatment options often arrive at ibogaine through word of mouth, veteran networks, or independent research. Because no legal treatment pathway exists in the United States, the regulated option is Brazil — where ibogaine has been prescribed by physicians and administered in hospitals for decades.
Nekawa combines that hospital-administered ibogaine pathway with a 15-day on-site integration program and 45-day at-home coursework on our 800-acre Costa Verde property near Paraty, Rio de Janeiro state.
How the Nekawa program works
The program begins with a discovery call and medical screening. Eligible participants travel to Brazil for physician evaluation, cardiac workup, and hospital-administered ibogaine treatment by independent licensed Brazilian doctors — followed by nature-based integration at Costa Verde.
Nekawa is a wellness education program. We prepare participants, support them through integration, and connect them with independent Brazilian physicians. We do not operate a clinic and do not prescribe or administer ibogaine.
Getting started
Book a discovery call to discuss your situation, medical history, and whether the Nekawa program is appropriate for you. Our team can walk americans through travel logistics, timeline, and what to expect before you commit.
Frequently asked questions
More questions? See our program FAQ.
Definitions
Plain-language definitions of the terms used on this page.
- Schedule I
- A US federal classification under the Controlled Substances Act for substances with no accepted medical use and high abuse potential. Ibogaine has been Schedule I since 1970, which means no clinic in the United States — public or private — can administer it.
- ANVISA
- Brazil's federal health agency, the Agência Nacional de Vigilância Sanitária — the functional equivalent of the US FDA. Regulates physician-prescribed, hospital-administered ibogaine treatment in Brazil under formal medical-use authorization.
- Window of Wonder
- The 2- to 12-week period of elevated neuroplasticity following an ibogaine session, during which the brain is more receptive to new patterns and integration work. Nekawa's 15-day on-site integration plus 45-day at-home coursework are structured around this window.
- eVisa (Brazilian)
- An electronic visa required for US travelers entering Brazil since January 1, 2026. Applied at brazil.vfsevisa.com, costs US$80.90, processes in roughly 72 hours, valid 10 years with multiple entries up to 90 days per stay.
- QT-interval
- A measurement on an electrocardiogram (EKG) of the time between ventricular depolarization and repolarization. Ibogaine prolongs the QT interval, which is why the prescribing physicians screen every patient with EKG and a comprehensive workup before clearing them for a session.
- Hospital-administered
- Refers to ibogaine treatment delivered in a hospital setting under continuous cardiac telemetry, ICU-trained nursing, and an on-site physician throughout — the regulated framework Brazil's prescribing physicians operate within. Distinct from retreat-style settings in countries without a federal regulatory pathway.
Vamos conversar.
Sem pressão — conte-nos um pouco sobre o que você está passando.
